Scion Pharmaceuticals

Scion Pharmaceuticals was a biopharmaceutical company focused on the discovery and development of small molecule drugs targeting ion channels. The company leveraged a proprietary drug discovery platform to identify modulators for a variety of therapeutic areas, including neuropathic pain, migraine, and central nervous system disorders. Founded in 2000 and backed by prominent venture capital firms, Scion developed a pipeline of candidates aimed at high-value ion channel targets. In 2005, the company was acquired by Wyeth Pharmaceuticals, which sought to integrate Scion's expertise and programs into its own neuroscience and pain research portfolios.